Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Neurocrine Biosciences

Neurocrine Shelves A Closely Watched Drug, But Stock Upbeat On Quarterly Win

Neurocrine Biosciences said Thursday its essential tremor study didn't pan out, and it shuttered the program. But NBIX stock jumped Friday.

Investors Business Daily

Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points

Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points

Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries.

Investors Business Daily

Dow Jones Futures: Snap Crash Hits Online Giants After Tesla Drives Market Rally Higher

Dow Jones Futures: Snap Crash Hits Online Giants After Tesla Drives Market Rally Higher

Tesla led the market rally Thursday, with a few more stocks setting up. But the Snap crash highlights this big risk.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Can IBD Stock Of The Day Neurocrine Biosciences Leapfrog Rivals For A $13 Billion Shot?

Neurocrine is the IBD Stock Of The Day. The biotech stock is approaching two potential entries as the movement disorder space heats up.

Investors Business Daily

IBD Screen Of The Day: These Top Stocks To Watch Outperform The Market

By scanning for stocks with a relative strength line at new highs in the IBD Stock Screener, we can look for these outperformers.

Investors Business Daily

Neurocrine Biosciences Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60 million, a 0.45% change since Q4.

Neurocrine Biosciences: Q1 Earnings Insights

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET

Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET

Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

What 8 Analyst Ratings Have To Say About Neurocrine Biosciences

What 8 Analyst Ratings Have To Say About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:

Where Neurocrine Biosciences Stands With Analysts

Where Neurocrine Biosciences Stands With Analysts

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:

Looking Into Neurocrine Biosciences's Return On Capital Employed

Looking Into Neurocrine Biosciences's Return On Capital Employed

Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.

Why Neurocrine Biosciences Are Trading Higher Today?

Why Neurocrine Biosciences Are Trading Higher Today?

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported

Recap: Neurocrine Biosciences Q4 Earnings

Recap: Neurocrine Biosciences Q4 Earnings

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine Biosciences reported an EPS of $0.04.

A Preview Of Neurocrine Biosciences's Earnings

A Preview Of Neurocrine Biosciences's Earnings

Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that Neurocrine Biosciences will likely report an Earnings Per Share (EPS) of $0.52.

Get all your
news in one place.

100’s of premium titles.
One news app.

Analyst Ratings For Neurocrine Biosciences

Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intuitive Surgical

Ollie Bargain Outlet

Quanta Services

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play